3-V Biosciences raises $28.5m in Series D
Oncology and infectious diseases company 3-V Biosciences has raised $28.5m in a Series D venture round co-led by NEA, Kleiner Perkins, Rock Springs Capital Management and Ally Bridge Group.
Oncology and infectious diseases company 3-V Biosciences has raised $28.5m in a Series D venture round co-led by NEA, Kleiner Perkins, Rock Springs Capital Management and Ally Bridge Group.